Allosteric modulators of solute carrier function: a theoretical framework.
allosteric modulator
drug design
linear free energy relationship
solute carrier
transition-state theory
Journal
Frontiers in physiology
ISSN: 1664-042X
Titre abrégé: Front Physiol
Pays: Switzerland
ID NLM: 101549006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
02
2023
accepted:
24
04
2023
medline:
30
5
2023
pubmed:
30
5
2023
entrez:
30
5
2023
Statut:
epublish
Résumé
Large-scale drug screening is currently the basis for the identification of new chemical entities. This is a rather laborious approach, because a large number of compounds must be tested to cover the chemical space in an unbiased fashion. However, the structures of targetable proteins have become increasingly available. Thus, a new era has arguably been ushered in with the advent of methods, which allow for structure-based docking campaigns (i.e., virtual screens). Solute carriers (SLCs) are among the most promising drug targets. This claim is substantiated by the fact that a large fraction of the 400 solute carrier genes is associated with human diseases. The ability to dock large ligand libraries into selected structures of solute carriers has set the stage for rational drug design. In the present study, we show that these structure-based approaches can be refined by taking into account how solute carriers operate. We specifically address the feasibility of targeting solute carriers with allosteric modulators, because their actions differ fundamentally from those of ligands, which bind to the substrate binding site. For the pertinent analysis we used transition state theory in conjunction with the linear free energy relationship (LFER). These provide the theoretical framework to understand how allosteric modulators affect solute carrier function.
Identifiants
pubmed: 37250134
doi: 10.3389/fphys.2023.1166450
pii: 1166450
pmc: PMC10210158
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1166450Informations de copyright
Copyright © 2023 Boytsov, Schicker, Hellsberg, Freissmuth and Sandtner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Med Chem. 2020 Apr 23;63(8):3834-3867
pubmed: 31774679
Cell. 2023 May 11;186(10):2160-2175.e17
pubmed: 37137306
Pharmacol Ther. 2021 Jun;222:107785
pubmed: 33310157
Chem Biol Drug Des. 2013 Jun;81(6):695-706
pubmed: 23574807
Curr Opin Pharmacol. 2009 Oct;9(5):580-8
pubmed: 19775937
J Biol Chem. 2021 Jul;297(1):100863
pubmed: 34118233
Pharmacol Rev. 2011 Sep;63(3):585-640
pubmed: 21752877
J Biol Chem. 2017 Mar 10;292(10):4235-4243
pubmed: 28096460
Nat Commun. 2021 Aug 20;12(1):5063
pubmed: 34417466
Pharmacol Ther. 2017 Jul;175:47-66
pubmed: 28223231
Trends Pharmacol Sci. 2020 Jul;41(7):446-463
pubmed: 32471654
Pharmacol Rev. 2020 Jul;72(3):558-604
pubmed: 32467152
Drug Discov Today. 2006 Mar;11(5-6):261-6
pubmed: 16580603
Nat Protoc. 2021 Oct;16(10):4799-4832
pubmed: 34561691
Bioinformatics. 2006 Feb 15;22(4):514-5
pubmed: 16317076
Mol Pharmacol. 2015 Jul;88(1):12-8
pubmed: 25873594
Sci Adv. 2021 Dec 03;7(49):eabl3857
pubmed: 34851672
J Mol Cell Biol. 2019 Jan 1;11(1):1-13
pubmed: 30239845
Pharmacol Rev. 2021 Oct;73(4):527-565
pubmed: 34907092
EMBO J. 2021 Jan 4;40(1):e105415
pubmed: 33185289
Nature. 2021 Dec;600(7890):759-764
pubmed: 34880501
Medchemcomm. 2016 Jun 1;7(6):1069-1081
pubmed: 27672436
Curr Top Med Chem. 2012;12(17):1869-82
pubmed: 23116466
Neuropharmacology. 2013 Sep;72:282-90
pubmed: 23632081
Membranes (Basel). 2021 Mar 03;11(3):
pubmed: 33802510
Methods Mol Biol. 2012;857:189-205
pubmed: 22323222
Pharmacol Rev. 2010 Mar;62(1):1-96
pubmed: 20103563
Curr Top Med Chem. 2009;9(9):755-70
pubmed: 19754393
Nature. 2016 Apr 21;532(7599):334-9
pubmed: 27049939
Trends Pharmacol Sci. 2015 Jan;36(1):41-50
pubmed: 25542076
Front Physiol. 2022 Feb 03;13:817886
pubmed: 35185619
J Biol Chem. 2015 Dec 25;290(52):31069-76
pubmed: 26504078
Trends Pharmacol Sci. 2018 Jul;39(7):659-671
pubmed: 29716746
Elife. 2018 Apr 26;7:
pubmed: 29697048
Elife. 2023 Jan 17;12:
pubmed: 36648438
Top Curr Chem. 2012;317:201-22
pubmed: 21710380
Br J Pharmacol. 2016 Oct;173(20):2934-51
pubmed: 26837045
Curr Opin Biotechnol. 2009 Aug;20(4):429-36
pubmed: 19733475
J Gen Physiol. 2019 Nov 4;151(11):1248-1264
pubmed: 31570504
Mol Pharmacol. 2019 Dec;96(6):851-861
pubmed: 31624135
Mol Pharmacol. 2019 Mar;95(3):303-312
pubmed: 30567955
Curr Opin Chem Biol. 2021 Jun;62:53-63
pubmed: 33689964
Eur J Med Chem. 2012 Jan;47(1):24-37
pubmed: 22071255
Nat Chem Biol. 2017 Nov;13(11):1143-1151
pubmed: 29045379